Empliciti (elotuzumab) for sale

Important Safety Information and Indications for EMPLICITIª, REVLIMIDª (lenalidomide), and
POMALYSTª (pomalidomide)

EMPLICITI in combination with REVLIMID and dexamethasone or in combination with POMALYST and dexamethasone may cause the following serious side effects:
Infusion reactions, infections, risk of developing new cancers (malignancies), and liver problems. There are also other serious risks (Boxed WARNINGS) associated with REVLIMID and POMALYST. REVLIMID and POMALYST can cause harm to unborn babies and blood clots. REVLIMID can also cause low blood counts. REVLIMID and POMALYST are only available through the REVLIMID REMSª or POMALYST REMSª programs. More information on the REMS programs is available at * or by calling 1-888-423-5436. For more safety information, please read the full Important Safety Information below. Your healthcare team will work with you to manage any side effects you may experience throughout your treatment with EMPLICITI with REVLIMID and dexamethasone or EMPLICITI with POMALYST and dexamethasone.
Important Safety Information and Indications

WARNINGS FOR REVLIMID: Risk to unborn babies, risk of low blood counts and blood clots.

WARNINGS FOR POMALYST: Risk to unborn babies, and blood clots.

What is the most important information I should know about REVLIMID & POMALYST?

Before you begin taking REVLIMID or POMALYST, you must read and agree to all of the instructions in the REVLIMID REMSª or POMALYST REMSª program. Before prescribing REVLIMID or POMALYST, your healthcare provider (HCP) will explain the REVLIMID REMS or POMALYST REMS program to you and have you sign the Patient-Physician Agreement Form.